Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments

Published:2021-03-20 Issue:9 Volume:39 Page:950-955
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Tannock Ian F.¹^ORCID,Ratain Mark J.²^ORCID,Goldstein Daniel A.³^ORCID,Lichter Allen S.⁴^ORCID,Rosner Gary L.⁵^ORCID,Saltz Leonard B.⁶^ORCID

Affiliation:

1. Princess Margaret Cancer Center, Toronto, ON, Canada

2. University of Chicago, Chicago, IL

3. Rabin Medical Center, Petach Tikvah, Israel

4. Value in Cancer Care Consortium, Ann Arbor, MI

5. Johns Hopkins University, Baltimore, MD

6. Memorial Sloan Kettering Cancer Center, New York, NY

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.20.02768

Reference62 articles.

1. Interventional Pharmacoeconomics—A New Discipline for a Cost-Constrained Environment

2. Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value

3. Abiraterone and Increased Survival in Metastatic Prostate Cancer

4. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

5. Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Projected environmental and public health benefits of extended-interval dosing: an analysis of pembrolizumab use in a US national health system;The Lancet Oncology;2024-06

2. The Lancet Commission on prostate cancer: planning for the surge in cases;The Lancet;2024-04

3. Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients;British Journal of Cancer;2024-03-26

4. Comparison of standard-dose and reduced-dose treatment of metastatic prostate cancer with enzalutamide, apalutamide or darolutamide: a rapid review;BMJ Oncology;2024-02

5. Optimizing the doses of cancer drugs after usual dose finding;Clinical Trials;2023-12-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3